Drug Trial Radar · NCT04169672
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Mar 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
248
Actual
Start
Dec 26, 2019
Primary completion
Feb 28, 2023
Study completion Feb 28, 2023
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Surufatinib single agent or Surufatinib combined with Toripalimab in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SurufatinibDrug
Surufatinib is a tablet in the form of 50mg, oral, once a day.
ToripalimabDrug
Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs) of safety run-in partTime frame: From Cycle 1 Day 1 to the end of Cycle 2 Day 7 (each cycle is 21 days)
- Objective response rate (ORR)Time frame: From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy(up to approximately 2 years)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.